HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Differin Gel Enters Changed Marketplace Since Last OTC Acne Drug Approval

This article was originally published in The Pink Sheet

Executive Summary

Galderma Labs' adapalene gel is pending launch as first OTC acne ingredient approved through an NDA and first new acne ingredient available OTC in 20 years, but company must play in a digitally-oriented marketplace.

You may also be interested in...



Nestle Pairs Nutrition Science Business With Pharma Firm Making Peanut Allergy Treatment

Nestle agrees to acquire Aimmune Therapeutics, maker of a drug indicated to reduce the severity of children’s allergic reactions to peanuts. It anticipates options to innovate in its consumer health children’s allergy business.

Health And Wellness Market News: X Out Acne Line In GNC, Eosera In Rite Aid

Proactiv marketer Guthy Renker introduces X Out acne line in GNC stores; Eosera reaches Rite Aid, plans extensions; ANSI meeting discusses supply chain safety, standards; and Dr. Reddy’s launches Mucinex D equivalent.

At Nuvothera, Rx Derma Veterans Develop OTCs For Serious Skin Conditions

Firm launched Prosoria in 2018 as a four-product topical line for inflammatory autoimmune disease psoriasis containing salicylic acid 3% combined with turmeric and other botanicals. CEO Arthur Clapp says firm will launch turmeric supplements and plans adding products for acne, eczema, warts, nail fungus and rosacea.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS123168

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel